Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CHAT | P28329 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3288977 | 1.00 | MEN1 (0.50) | MEN1KMT2AHTR2ARELAMAOB | |
| SCHEMBL10619673 | 0.83 | MAOB (0.42) | MEN1KMT2AHTR2AMAOBCYP1A2 | |
| SCHEMBL29055535 | 0.83 | MAOB (0.42) | MEN1KMT2AHTR2AMAOBCYP1A2 | |
| SCHEMBL27689872 | 0.82 | MEN1 (0.46) | MEN1KMT2AHTR2ARELAMAOB | |
| SCHEMBL9426848 | 0.80 | MEN1 (0.51) | MEN1KMT2AHTR2ARELAMAOB | |
| SCHEMBL16874337 | 0.78 | MEN1 (0.50) | MEN1KMT2AHTR2ARELAMAOB | |
| Iodide SCHEMBL31210332 | 0.78 | MEN1 (0.50) | MEN1KMT2AHTR2ARELAMAOB | |
| SCHEMBL489023 | 0.78 | MEN1 (0.50) | MEN1KMT2AHTR2ARELAMAOB | |
| SCHEMBL11861151 | 0.77 | CHAT (0.46) | MEN1KMT2AHTR2ARELAMAOB | |
| SCHEMBL11983844 | 0.77 | CHAT (0.46) | MEN1KMT2AHTR2ARELAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718815-B2 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-05-18 | — | — | US | disclosed |
| US-20080132567-A1 | Alpha-Aminoamide Derivatives Useful in the Treatment of Lower Urinary Tract Disorders | NEWRON PHARMACUETICALS S.P.A (IT) | 2008-06-05 | — | — | US | disclosed |
| WO-2005070405-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF LOWER URINARY TRACT DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-08-04 | — | — | WO | disclosed |
| EP-1557166-A1 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-07-27 | — | — | EP | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132567-A1 | Alpha-Aminoamide Derivatives Useful in the Treatment of Lower Urinary Tract Disorders | AADAT, BCAT2, DNPEP | MEN1 2153/4885KMT2A 1010/4885HTR2A 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.